Bezlotoxumab (MK-6072) Versus Placebo in Children With Clostridium Difficile Infection (CDI) (MK-6072-001)

NCT03182907 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

148

Enrollment

INDUSTRY

Sponsor class

Conditions

Clostridium Difficile Infection

Interventions

BIOLOGICAL: Bezlotoxumab
DRUG: Placebo
DRUG: Antibacterial drug treatment (ABD)

Sponsor

Merck Sharp & Dohme LLC